human_pharmacology_study · 1999

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Gobburu JV, Agersø H, Jusko WJ, Ynddal L · Pharmaceutical Research

low_to_moderateDOI · 10.1023/a:1018955126402PMID · 10496658Verified

Plain-English summary

Ipamorelin caused a short-lived pulse of growth hormone in healthy volunteers, but the study did not test muscle gain, recovery or other clinical benefits.

Population

Healthy adult volunteers

Sample size

Intervention

Single intravenous doses of ipamorelin

Outcomes measured

Ipamorelin pharmacokinetics|Growth hormone response|Tolerability

Key findings

Exposure was dose-proportional and growth hormone peaked rapidly before declining toward baseline.

Funding & disclosures

Commercial development context; full disclosure details should be checked in the article.

Limitations

Small early-phase study with biomarker endpoints and no long-term safety or efficacy assessment.

Risk of bias

Moderate — objective pharmacokinetic endpoints but limited sample and early development context.

Citation

Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. https://doi.org/10.1023/a:1018955126402

Linked peptides in the PeptiBrief database

→ Ipamorelin